Skip to main content

CCTG Connection



Published:
Category: Group updates
CCTG Patient Representatives are in high demand. Recently some of our committee members have had the opportunity to share their experiences and expertise at stakeholder events both nationally and internationally. Read More

Published:
Category: Group updates
CCTG is seeking a Senior Investigator

CCTG seeking an outstanding and visionary cancer trialist for the position of Senior Investigator (SI). Expertise in cancer clinical trial methods and conduct is required.

Read More

Published:
Category: Trials
Closed to Accrual: CEC27
The CEC7 Study a Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease has closed to further accrual after meeting its accrual target.
 
This phase III trial studies how well single fraction stereotactic radiosurgery works compared with fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body and has been removed by surgery.
Read More

Published:
Category: Trials
CCTG HN11 SELECT trial is now open

The CCTG HN11 SELECT study has now opened to accrual across Canada and sites in the US. The trial is a randomized, controlled, phase III clinical trial for patients with lateralized oropharyngeal carcinoma (OPC) and will compare the effectiveness of standard radiotherapy to personalized radiotherapy guided by the lymphatic mapping technique using SPECT-CT.

Read More



Published:
Category: Group updates
Canadian Thanksgiving Monday October 10

A reminder that this weekend is Canadian Thanksgiving and the CCTG Central Offices will be closed on Monday, October 10th. All of the online applications will still be available and regular office hours resume on Tuesday October 11th at 8:30am. Happy Turkey Day!

Read More

Published:
Category: Publications

Updated 5-year results of the Unicancer PRODIGE-24 | CCTG PA6 trial confirmed the significant improvement in all outcomes, including overall survival, with mFOLFIRINOX regimen compared to gemcitabine in adjuvant setting for for patients with pancreatic cancer has been published in JAMA Oncology.

Read More

Published:
Category: Trials
Closed to Accrual: CXC2

CXC2 a Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer is now closed to accrual as the accrual target has been met.

Read More



Published:
Category: Group updates